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ABSTRACT
There are outstanding studies on the importance of survivin and inhibition of apoptosis in many cancers, including lung. Evaluation of 
the relationship between survivin expression in lung cancer and prognosis is the aim of this study. A total of 50 patients with a diagno-
sis of squamous cell lung carcinoma were included in this study.  Survivin levels that were obtained with IHC (immunohistochemical) 
and RT-PCR (reverse transcription-polymerase chain reaction) methods from the tumor and metastatic lymph node tissues embed-
ded in paraffin blocks were evaluated along with clinical parameters. The median age of the patients was 60 years (range 54-69). All 
patients were male and all of them were smokers. The mean duration of follow-up and disease-free survival was 42.08±22.46 months 
and 40.62±22.46 months, respectively. Significant associations were found among survivin levels in metastatic lymph nodes and 
duration of smoking (IHC and RT-PCR), angiolymphatic invasion (IHC), the number of mitosis (RT-PCR) ( p= 0.05 and p= 0.05, p< 
0.001, p= 0.02, respectively). Survivin showed statistically significant associations with angiolymphatic invasion and stage in multivari-
ate analysis (p< 0.001, p= 0.04, respectively). An association was not found between survivin levels in tumor and lymph nodes and 
survival.  Higher survivin levels in lymph nodes detected by IHC was associated with shorter survival but that didn’t reach statistical 
significance (65.22±5.16 vs 42.33±11.97, p= 0.72). Further larger studies done with larger numbers of patients are required in order 
to evaluate its effects in our society. 
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ÖZET
Skuamoz Hücreli Akciğer Kanserinde Survivin Ekspresyonu ve Prognostik Korelasyonu
Akciğer kanseri de dahil olmak üzere birçok kanserde apopitozis inhibisyonu ve survivinin önemine değinen önemli çalışmalar 
bulunmaktadır. Bu çalışmanın amacı akciğer kanserinde survivin ekspresyonu ile prognoz ilişkisini değerlendirmektir. Skuamoz hücreli 
akciğer kanseri tanılı toplam 50 hasta çalışmaya alındı. Tümör ve metastatik lenf nodlarında survivin düzeyi İHK (İmmunhistokimya) 
ve RT-PCR (reverz transkripsiyon-polimeraz zincir reaksiyonu) yöntemleri ve klinik parametrelerle beraber değerlendirildi. Hastaların 
median yaş değeri 60 yıl (sınırlar 54-69) idi. Hastaların hepsi erkekti ve hepsi sigara içicisiydiler. Ortalama takip süresi 42.08±22.46 ay, 
hastalıksız sağkalım süresi ise 40.62±22.46 ay olarak hesaplandı. Metastatik lenf nodundaki survivin düzeyiyle, sigara içme süresi (İHK 
ve RT-PCR), anjiyolenfatik invazyon varlığı (İHK) ve mitoz sayısı (RT-PCR) arasında anlamlı ilişki saptandı (sırasıyla p= 0.05, p= 0.05, p< 
0.001, p= 0.02). Mutivariet analizde survivin ile anjiyolenfatik invazyon varlığı ve evre arasında anlamlı ilişki bulundu (sırasıyla, p< 0.001, 
p= 0.04). Tümör ve lenf nodundaki survivin seviyesi ile sağkalım arasında anlamlı ilişki bulunamadı. Lenf nodunda İHK ile saptanan 
yüksek survivin düzeylerinde sağkalım daha kısa olmakla beraber istatistiksel olarak anlamlılık saptanmadı. Toplumumuzda survivinin 
prognostik ve prediktif önemini belirlemek için daha fazla hasta sayısıyla yapılacak daha kapsamlı çalışmalara ihtiyaç vardır.
Anahtar Kelimeler: Survivin, Skuamoz hücreli akciğer kanseri, Sağkalım
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INTRODUCTION
Lung cancer consists 12% of all cases of cancer 
globally. It occupies the second place among caus-
es of cancer-related deaths in males and females.1,2 
Smoking is the most important etiologic factor in 
the development of lung cancer. The risk of lung 
cancer is 20 times higher in smokers in compari-
son to non-smokers. Age to start smoking, total 
duration of smoking, total number of cigarettes 
smoked, are all effective on the risk.3
Recently, some targets related to adenocarcinoma 
subtype were detected and drugs targeting them 
were developed, but for squamous cell carcinoma 
until now there is no such type of specific target. 
The first line of therapy for this histological type 
is chemotherapy. Studies on determination of bio-
markers for predicting prognosis and response to 
chemotherapy have increased recently. 
Apoptosis is a process which is important in both 
carcinogenesis and cancer treatment.4-6 There are 
outstanding studies on the importance of survivin 
and inhibition of apoptosis in many cancers, in-
cluding breast, lung, esophagus, stomach, head-
neck, and cervix.7-11
Survivin is a protein which is made up of 142 ami-
no acids of 16.5 kD, and is an apoptosis inhibitor. It 
is the smallest member of IAP (inhibitor apoptotic 
protein) family in mammals.12 According to some 
studies surviving may act as a target for cancer 
treatment and as a prognostic marker.13-14
There is no data on the literature evaluating the 
correlation between survivin in squamous cell 
subtype and clinicopathological parameters and 
survival. There are recent notable studies evaluat-
ing the relationship between especially response to 
chemotherapy, EGFR resistance and surviving.15-18
In this study, the relationship between survivin in 
both tumor and metastatic lymph nodes and clin-
icopathological parameters and survival in patients 
with squamous cell non-small cell lung cancer, 
which is more frequently seen in our country were 
evaluated. The study was approved by the Ethics 
Committee of Pamukkale University and scientific 
investigation project.
PATIENTS AND METHODS
A total of 50 patients with squamous cell lung car-
cinoma, stages between 1-3, who had undergone 
pneumonectomy, lobectomy, or wedge resection, 
who had not received neoadjuvant chemotherapy 
or radiotherapy, treated and followed-up by the Pa-
mukkale University Medical School Department 
of Medical Oncology between the years 2005-2013 
were examined retrospectively. The demographic 
data of the patients, tumor types, chemotherapies 
received were extracted from the patient files. The 
patients were detected from the patient follow-up 
files of Outpatient Clinics of Medical Oncology, 
and the stages, duration of survival were examined 
statistically at the end of study.
Determination of survivin expression with IHC 
method: The diagnosis of lung carcinoma, tumor 
differentiation in the histological sections of resec-
tion materials, and the presence of metastatic lymph 
node in lymph node dissection materials were re-
examined and re-evaluated. The samples that best 
reflected the tumor tissue were selected. Five 3 
micron sections were taken for the purpose of sur-
vivin antibody examination to positive – charged 
glasses from selected paraffin blocks for each case. 
The tissue samples were left at 500C for one night 
in the incubator for deparaffination. They were lat-
er dyed automatically with the help of VENTANA, 
Benchmark LT device. In sections dyed automati-
cally, 1/200 diluted survivin antibody (Anti-BIRC5 
policlonal rabbit antibody, BiOSs, Woburn, USA) 
was used and the targeted proteins were visualized. 
The duration of incubation with antibodies was 36 
minutes for survivin. After which, it was held in 
70% alcohol for 2 minutes, in 80% alcohol for 2 
minutes, in 95 % alcohol for 2 minutes and abso-
lute alcohol for 2 minutes, sequentially. The sec-
tions were dried in the air and held in Xylene for 
15 minutes, and closed with entellan.
Survivin expression was determined in the cy-
toplasm. Cytoplasmic staining was considered 
positive for survivin, and other staining were con-
sidered negative in the evaluation. Cytoplasmic 
survivin staining was recorded in between 0-100 
% according to diffusiveness. Staining of 50% and 
more of the cells was considered as an increased 
survivin expression (Picture 1).
Determination of survivin expression with RT-PCR 
method: Both tumor tissues of patients and also 10 
µm sections of lymph nodes in terms of distant or-
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gan metastasis were transported to sterile ependorf 
tubes. These were incubated at 56° C for 20 min-
utes with xylene in order to remove paraffin from 
these tissues. Afterwards, paraffin was removed by 
centrifugation at 14000xg for 2 minutes. After this 
procedure, xylene was removed with use of 96% 
absolute alcohol.  After centrifugation at 14000 
xg for 2 minutes, the supernatant was removed. 
The pellet was incubated at 56°C for 15 minutes 
for evaporation of alcohol from the environment. 
Then, RNA was isolated with use of qiagen FFPE 
isolation (kat:73504 Germany) kit. The RNA thus 
obtained was measured with a nanodrop and was 
stored at  -80°C. After total RNA levels of all pa-
tients were obtained, total RNAs were turned into 
cDNA with the help of qiagen cDNA (Kat:679923 
France) synthesis kit. The protocol was as fol-
lows; 5x tampon 5µl, dNTP 100 nM, random na-
nomer 5,2 µl, reverse transcriptase 1 µl, DTT 1,25 
µl, RNAse inhibitor 0,5µl, sample 10 µl reaction 
complex were prepared. cDNA was obtained af-
ter incubations at 650C for 5 minutes, on ice for 
5 minutes, at 250C for 10 minutes, at 500C for 60 
minutes and at 850C for 5 minutes and measured 
at nanodrop.  For investigation of real-time PCR 
with obtained cDNA, survivin (Roche Applied Sci-
ence Basel Switzerland), caspase 9 (Roche Applied 
Science Basel Switzerland) and beta actin (Roche 
Applied Science Basel Switzerland) gene expres-
sions were examined. The reaction conditions were 
as follows: 10 minutes at 950C for 1 cycle, at 950C 
for 10 seconds, at 600C for 30 seconds, at 720C for 
1 second (reading) for 45 cycles and cooling was 
done at 400C for 30 seconds. Calculations were 
done with the ratio of obtained beta actin cycle 
number with the other target gene (delta ct). Me-
dian values were determined from results obtained 
from tumor and lymph nodes. Survivin values of 
1.4 and more in the tumor, and 0.52 and over in the 
lymph node were considered as increased.
Statistical Analysis
SPSS version 17 was used in the statistical analy-
sis. Descriptive statistics were presented as mean, 
standard deviation and percent. Significance of 
differences between the groups was evaluated 
Picture 1. Higher expression level of survivin in poorly differ-
entiated tumors
Table 1. The histopathological characteristics of the patient
Characteristics Patient, n (%) Mean±SD
Age (year) - 61.94±7.61
Gender  
 Male 50 (100) 
 Female 0 (0) 
Smoking 
 Yes 50(100) 
 No 0 (0) 
Smoking time (month) - 29.60±8.91
Operation 
 Lobectomy 29 (58) 
 Pneumonectomy 20 (40) 
 Wedge resection 1 (2) 
Lymph node metastasis 
 Yes 21 (42) 
 No 29 (58) 
Stage 
 1-2 45(90) 
 3 5 (10) 
Tumor localization 
 Central 33 (66) 
 Peripheral 17 (34) 
Tumor differentiation 
 Poor 12 (24) 
 Moderate-well 38 (76) 
Tumor mitotic count - 7.86±3.05
Angiolymphatic invasion 
 Yes 28 (56) 
 No 22 (44) 
Adjuvant chemotherapy  
 Yes 22 (44) 
 No 28 (56) 
Adjuvan radiotherapy 
 Yes 3 (6) 
 No 47 (94) 
Metastasis 
 Yes 9 (18) 
 No 41 (82) 
Progression-free survival - 40.62±22.46
      (month)
Overall survival (month) - 42.08±20.68
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with Mann-Whitney U test. Associations between 
quantitative data were determined with the help 
of Spearman correlation test. Progression-free 
and overall survival was calculated with Kaplan–
Meier. Log-rank was used for statistical signifi-
cance and p< 0.05 was considered as statistically 
significant. In evaluation of tumor and lymph node 
survivin levels in multivariate analysis, linear re-
gression was used and cox regression analysis was 
used for evaluation of survival duration. 
RESULTS
The median age of 50 patients included in this 
study was 60 years (range, 54-69). All of the pa-
tients were males and all had a history of past 
smoking. Twenty-two (44%) patients had re-
ceived adjuvant chemotherapy, 3 patients (6%) 
had adjuvant radiotherapy. Twenty nine patients 
had undergone (58%) lobectomy, 20 had under-
gone pneumonectomy (40%), 1 patient (2%) had 
undergone wedge resection. In histopathological 
examination, 12 of the patients had poor differen-
tiated morphology, whereas 38 showed moderate-
well differentiation. The tumor diameter was 1 cm 
at its smallest point, and 10 cm at its largest, with 
a mean value of 4.01±2.09 cm. The tumor had a 
central location in 33 (66%) patients, and periph-
eral location in 17 (34%) patients. In histopatho-
logical examination, the mean number of mitosis 
in the tumor was 7 (range, 4-10). Of the patients, 
28 (56.0%) had angiolymphatic invasion, and 21 
(42%) had lymph node metastasis. Forty-five pa-
tients (90%) were at stage 1 and 2, 5 patients (10%) 
were at stage 3. The mean duration of follow-up 
was 42.08±20.68 months in 50 patients. The mean 
disease-free duration of survival of the patients 
was 40.62±22.46 months, and the general dura-
tion of survival was 42.08±20.68 months. The his-
topathological characteristics of the patients are 
presented in Table 1.  The mean survivin level in 
the tumor was 74.70±27.30 with IHC method; and 
Table 2. Associations between survivin levels in metastatic lymph nodes and histopathological characteristics of the patients
 Level of survivin in metastatic lympnode
                   IHC           RT-PCR
 
Characteristics  n  Mean±SD p Mean±SD p 
Age (year) <65 32 19.44±32.80 0.09 0.33±0.82 0.70
 >65 18 37.03±42.67  0.44±0.96 
Smoking time ≤30 pocket/year 23 20.65±36.19 0.05* 0.12±0.43 0.05*
 >30 pocket/year 27 39.25±41.68  0.58±1.07 
Mitotic count Low (≤7) 26 30.57±39.65 0.88 0.27±0.97 0.02*
 High (>7) 24 30.83±41.16  0.48±0.74 
Operation Lobectomy 29 22.06±37.35 0.09 0.38±0.98 0.73
 Pneumonectomy 20 44.75±41.15  0.37±0.71 
 Wedge resection 1 1.00±0.00  1.00±0.00 
Stage 2 45 26.33±39.57 0.03* 0.36±0.89 0.28
 3 5 70.00±14.14  0.50±0.68 
Tumor localization Peripheral 17 29.24±40.11 0.63 0.36±0.97 0.32
 Central 33 33.52±40.76  0.39±0.65 
Tumor differentiation Poor 12 14.16±33.15 0.09 0.31±0.56 0.72
 Moderate-well 38 35.92±40.89  0.39±0.95 
Angiolymphatic invasion Yes 28 50.17±41.91 <0.001* 0.43±0.88 0.36
 No 22 5.90±17.90  0.30±0.86 
Metastasis Yes 9 33.53±41.20 0.47 0.41±0.91 0.65
 No 41 17.77±32.70  0.20±0.62 
* Univariate analysis is obtained and analysed by using Mann Whitney U and Kruskal-Walles tests. p< 0.05 is accepted to be statistically significant
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30.70±39.9 in the lymph node. According to ex-
tensiveness of cytoplasmic survivin staining, val-
ues between 0-100% were found. Staining of 50% 
and more of the cells was considered as evidence 
of increased survivin expression. As there are no 
studies in the medical literature examining sur-
vivin levels in metastatic lymph nodes, survivin in 
lymph nodes was considered as in the tumor. The 
mean survivin value in the tumor was found to be 
2.44±2.94 with PCR method, and 0.37±0.86 in the 
lymph node. For the survivin values determined 
with PCR method, threshold value for the tumor 
was 1.39 with ROC analysis and it was 0.51 for the 
lymph node. No correlations were found between 
survivin levels determined with IHC and PCR 
methods in the tumor. Also, there were no associa-
tions between survivin levels determined with IHC 
and PCR methods in the lymph nodes (p> 0.05). 
As it is shown in Table 2, significant associations 
were found between survivin levels in metastatic 
lymph nodes and the duration of smoking (IHC 
and RT-PCR), angiolymphatic invasion (IHC) and 
the number of mitosis (RT-PCR) ( p= 0.05 and p= 
0.05, p< 0.001, p= 0.02, respectively). There was a 
significant association between angiolymphatic in-
vasion and stage with survivin levels in multivari-
ate analysis (p< 0.001, p= 0.04, respectively). In 
survivin levels which were found to be increased 
in the lymph node with IHC, OS was shorter but 
it did not reach statistical significance (65.22±5.16 
vs 42.33±11.97, p= 0.72). An association was not 
found between survivin levels in the tumor and 
lymph node and OS (Figure 1 and 2). Only lymph 
node metastasis were significantly correlated with 
OS in multivariate analysis (p= 0.001) (Tables 3, 4).
Table 3. Associations between survivin levels in the tumor 
and lymph node and OS
  Mean±SD p
Age (year) 
 ≤65 62.23±4.27 0.78
 >65 63.58±5.46 
Lymph node metastasis 
 No 63.66±5.10 0.79
 Yes 61.05±4.65 
Stage 
 1-2 62.79±3.62 0.97
 3 60.00±10.73 
Angiolymphatic invasion 
 No 64.33±4.33 0.59
 Yes 59.43±5.67 
Tumor differentiation 
 Poor 62.15±4.01 0.73
 Moderate-well 62.25±6.29 
Adjuvant Chemotherapy 
 No 50.45±4.78 0.01
 Yes 72.52±2.39 
Metastasis 
 No 73.46±1.51 p<0.001
 Yes 18.33±2.36 
Smoking time 
 <30 pocket year 66.98±3.34 0.02
 ≥30 pocket year 47.26±8.10 
Level of survivin in tumor cell by IHC 
 Low (<%50) 60.97±3.49 0.73
 High (>%50) 59.62±9.41 
Level of survivin in tumor cell by RT-PCR 
 Low (≤1.39) 62.04±4.52 0,62
 High (>1.39) 61.26±4.90 
Level of survivin in metastatic lympnode by IHC 
 Low (<%50) 65.22±5.16 0.72
 High (>%50) 42.33±11.97 
Level of survivin in metastatic lympnode by RT-
PCR 
 Low (≤0.51) 68.50±5.21 0.32
 High (>0.51) 61.07±4.06 
 
* Univariate analysis is obtained and analysed by using Mann Whitney 
U and Kruskal-Walles tests. 
Table 4. Associations between survivin levels in the tumor and lymph node and OS in multivariate analysis
 Beta 95%CI  p value
Adjuvant  chemotherapy 6.03 0.45 80.93 0.17
Metastasis 112.78 7.35 1725.53 0.001*
Smoking time 0.83 0.14 4.78 0.84
Level of survivin in tumor cells by IHC 1.04 0.10 10.38 0.96
Level of survivin in metastatic lympnode by IHC 3.04 0.16 55.60 0.45
* p values are obtained by lineer regression analysis. p < 0.05 is accepted to be statistically significant
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DISCUSSION
Survivin is expressed in embrionic cells and malig-
nant cells, but it is not expressed in mature-differ-
entiated cells.19 The relationship between survivin, 
which is an anti-apoptotic protein, and a number 
of cancers were documented. It may show differ-
ent functions according to the locations. Survivin, 
which is a member of IAP family inhibits apoptosis 
by inhibiting caspase 3 and 7.20
When the level of expression is evaluated, more 
survivin expression was reported in the study by 
Falleni et al. in patients with squamous cell lung 
cancer in comparison with adenocarcinoma and 
large cell subtypes.21 In the studies by Sun, Huang 
no differences in expression were found between 
histological subtypes.22,23
Its prognostic value was assessed but clinicopatho-
logical correlations were not examined in any stud-
ies.24-30 In terms of data on its prognostic signifi-
cance, there are studies in which it was found to be 
a marker of poor prognosis, while there are other 
studies which have found the contrary.25-27 Also, 
there are no studies in the literature investigating 
the relationship between metastatic lymph node 
and clinical characteristics and survival in squa-
mous cell subtype. Small groups of patients with 
squamous cell and adenocarcinoma were exam-
ined in these studies. A total of 225 patients with 
adenocarcinoma and 148 patients with squamous 
cell carcinoma were evaluated in the study by Sun 
et al, which may be considered as the most exten-
sive investigation, and prognostic significance was 
not found in patients with squamous cell carcino-
ma.22 There are no studies in which metastasis was 
investigated along with the tumor tissue. Accord-
ing to our study, it may be stated that it is one of the 
factors that contribute to progression. In terms of 
survival, the inverse relationship between survivin 
levels and survival in lymph node metastasis may 
provide an important clue for us, although it did 
not reach statistical significance. Along with data 
showing that survivin m-RNA levels may be effec-
tive in predicting response to anti-EGFR agents, 
there is also data that it may be effective in over-
Figure 1. (A) Overall survival rate with IHC methods in tumor 
cells survivin levels; (B) Overall survival rate with PCR methods 
in tumor cells survivin levels
Figure 2. (A) Overall survival rate with IHC methods in lymph 
node survivin leves; (B) Overall survival rate with PCR methods 
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coming resistance to therapy with tyrosine kinase 
inhibitors.15,31
It is also not clear how survivin levels should be 
evaluated. In a literature evaluation, values be-
tween 10-50% were found to be reported in stud-
ies with IHC method.32  Furthermore, the threshold 
value with PCR method in the literature is different 
in each study.33,34 A correlation between IHC and 
RT-PCR was not found in our study. But a conclu-
sion may be reached with large-scale studies evalu-
ating both methods together. 
When racial differences are considered, it is hard 
to reach a conclusion, as there are no studies evalu-
ating the relationship between survivin and squa-
mous cell lung cancer in our society. Another im-
portant problem preventing conclusions in other 
racial groups is the larger number of studies on 
Asian populations.
The limitations of our study include the absence of 
control groups, the small sample size. Limitations 
in labour and economic conditions prevented us to 
overcome these limitations. 
CONCLUSION 
Survivin expression increases during the metastatic 
process and shows a negative correlation with OS. 
Higher survivin levels in lymph nodes detected by 
IHC were associated with shorter survival. An as-
sociation was not found between survivin levels 
in tumor and lymph nodes and survival. Further 
larger studies done with larger numbers of patients 
are required in order to evaluate its effects in our 
society. Due to heterogeneity in the studies, more 
homogenous data are needed to assess survivin in 
squamous lung cancer. Also, combinations with 
targeted agents and immunotherapy may contrib-
ute in the prevention of resistance, and we believe 
that detailed investigations on this issue in the fu-
ture may provide an effective strategy in increasing 
the probability of cure. 
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